NEW YORK, NY / ACCESSWIRE / November 30, 2023 / Levi & Korsinsky notifies investors that it has commenced an investigation of Legend Biotech Corporation ("Legend") (NASDAQ:LEGN) concerning possible violations of federal securities laws.

On November 28, 2023, the U.S. Food and Drug Administration ("FDA") announced that it was "investigating the identified risk of T cell malignancy with serious outcomes, including hospitalization and death, and is evaluating the need for regulatory action" after "receiving reports of T-cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in patients who received treatment with BCMA- or CD19-directed autologous CAR T cell immunotherapies." The FDA's press release listed Legend's Carvykti (ciltacabtagene autoleucel) as among the approved products in the class of products at issue. On this news, Legend's stock price fell $1.57 per share to close at $59.99 per share on November 28, 2023. To obtain additional information, go to:

https://zlk.com/pslra-1/legend-lawsuit-submission-form?prid=57918&wire=1

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212)363-7500.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171
https://zlk.com/

SOURCE: Levi & Korsinsky, LLP